Results 71 to 80 of about 8,884 (175)

Mapping Obesity Care Pathways and Healthcare Resource Use From 2015 to 2019 in England

Obesity Science &Practice, Volume 12, Issue 4, August 2026.
ABSTRACT Objective This observational study characterized obesity care pathways and healthcare resource use in England between 2015 and 2019. Methods Data were obtained from Discover and the Salford Integrated Record (SIR), two databases of linked primary and secondary electronic health records in England. Adults with a body mass index (BMI) ≥ 30 kg/m2
Alexander Dimitri Miras, Silvia Capucci, Sylwia Migas, Bozydar Wrona, Liwei Zhao, Johann Castañeda‐Sanabria, Lise M. Hagelund, Vasileios Antavalis, Camilla S. Morgen   +8 more
wiley   +1 more source

A Service Evaluation of a Specialist Multi‐Disciplinary Weight Management Service Based in Primary Care Including Long‐Term Follow‐Up Data

Clinical Obesity, Volume 16, Issue 4, August 2026.
ABSTRACT This service evaluation of a primary care‐based specialist weight management service reports data from 1094 patients over 5 years (2014–2019), including weight data at 1‐year post‐discharge. The results show clinically and statistically significant improvements in weight, diet, physical activity, quality of life, blood pressure and blood ...
Helen M. Parretti, Carly A. Hughes, Sally Erskine, Nicholas Steel, Amy Jennings   +4 more
wiley   +1 more source

Orlistat targets NEDD8 conjugating enzyme UBC12 for cancer therapy

Pharmacological Research
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide, and one of the best-characterized drivers is oncogenic Wnt signaling.
Mengzhen Shen, Huihui Li, Ying Xuan, Hongyan Zhu, Lizhe Chen, Piliang Hao, Chengqian Zhang, Jiansong Fang, Xianglian Zhou, Rong Yan, Yi Qu, Xisong Ke   +11 more
doaj   +1 more source

Impact of Orlistat-Induced Weight Loss on Diastolic Function and Heart Rate Variability in Severely Obese Subjects with Diabetes

Journal of Obesity, 2011
Objective. Determine the impact of Orlistat-induced weight loss on metabolic profile and cardiovascular function in severely obese patients with type 2 diabetes. Methods.
Julie Martin, Carmen Paquette, Simon Marceau, Frédéric-Simon Hould, Stéfane Lebel, Serge Simard, Jean-Gaston Dumesnil, Paul Poirier   +7 more
doaj   +1 more source

Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6787-6800, August 2026.
ABSTRACT Aims To quantify real‐world diagnosis and treatment of obesity in Sweden, describe cardiometabolic comorbidity burden across obesity classes, and compare long‐term cardiovascular outcomes with the general population. Materials and Methods This population‐based cohort study used the AROS (Analysis of Real‐world data of patients with Obesity in ...
Viveca Ritsinger, Magnus Sundbom, Jonatan Dereke, Åsa Ericsson, Thomas Cars, Maria K. Svensson, Anna Norhammar   +6 more
wiley   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6482-6508, August 2026.
ABSTRACT Aims We aimed to examine the association between GLP‐1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. Materials and Methods A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was conducted from database inception through December 11, 2025. Observational studies investigating
Timothy H. Chan, Leon E. Cosler, Michael R. Gionfriddo, Emily E. Leppien, Eleanor J. Sommers, Mia E. Lussier   +5 more
wiley   +1 more source

Dynamics of lipid profile and circadian pressure rhythms in patients with obesity and arterial hypertension, treated with orlistat and its combination with ACE inhibitors

Кардиоваскулярная терапия и профилактика, 2005
Aim. To assess effects of orlistat and its combimation with enalapril on main cardiovascular risk parameters in young patients with obesity and arterial hypertension. Material and methods.
A. G. Avtandilov, A. S. Ametov, A. K. Ausheva, A. K. Bolotseva   +3 more
doaj  

Risk of Age‐Related Ocular Diseases in Non‐Diabetic Adults With Obesity Using Glucagon‐Like Peptide 1 Receptor Agonists

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7580-7591, August 2026.
ABSTRACT Aims To assess whether glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are associated with a lower incidence of age‐related ocular diseases in non‐diabetic older adults with overweight or obesity. Materials and Methods We conducted a retrospective, propensity score–matched cohort study using the TriNetX global research network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients

Therapeutics and Clinical Risk Management, 2017
Rashid Ali Khan,1 Prem Kapur,2 Abhinav Jain,3 Farrukh Farah,4 Uma Bhandari11Department of Pharmacology, Faculty of Pharmacy, 2Department of Medicine, 3Department of Radiology, 4Department of Paramedical Sciences, Hamdard Institute of Medical Sciences ...
Ali Khan R, Kapur P, Jain A, Farah F, Bhandari U   +4 more
doaj